Business Of Biotech

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing  a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain. Dr. Bazan explains his strategy for building value through small raises and no full-time salaried employees, co-founding the company with his father -- a scientist and director of the Neuroscience Center of Excellence at Louisiana State University Health Sciences Center -- and why the future of pain management will likely involve multimodal approached personalized to individual patients.  This episode of the Business of Biotech is brought to you by Ecolab.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO.  This episode of the Business of Biotech is brought to you by Ecolab.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies. Amber talks about FSHD, a progressive muscular dystrophy, how the company raised $68 million in Series B funding despite challenging market conditions, her partnership with Springbok Analytics for AI analysis of MRI images, working with a CDMO to manufacture a new treatment modality, and navigating the FDA during a time of disruption.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]

We love to hear from our listeners. Send us a message. [https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms] On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy. Her experiences in politics, law, and biopharma government affairs uniquely positions her to navigate complex policy challenges while creating opportunities for biotech upstarts across New York and beyond. Jennifer also highlights key programs, capabilities, and funding on offer to early-stage biotech companies.  This episode of the Business of Biotech is brought to you by Ecolab Life Sciences. Learn more at https://www.ecolab.com [https://www.ecolab.com/]. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech [https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl] tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter [https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/]. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/ [https://www.linkedin.com/in/matthewpillar/]